Antibody-Drug Conjugate

Phase 2Small molecule

Antibody-Drug Conjugate is one of 100 small molecule programs targeting Esophageal Carcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Esophageal CarcinomaNot yet recruiting

LymphomaActive, not recruiting

SepsisActive, not recruiting

Metastatic Soft-Tissue SarcomaRecruiting

Advanced Refractory Solid TumorsRecruiting

Esophageal CarcinomaPhase 1

Not yet recruiting

LymphomaPreclinical

Active, not recruiting

SepsisPreclinical

Active, not recruiting

Metastatic Soft-Tissue SarcomaPreclinical

Recruiting

Advanced Refractory Solid TumorsPhase 2

Recruiting

Competition

Competitive Landscape

370 competitors in Lymphoma

#DrugCompanyPhaseTrials

Antibody-Drug Conjugate

MMBrace Therapeutics

Phase 2

1 2

Zofran

Novartis

Preclinical

2 3

Cabenuva

GSK

Preclinical

1 4

Norvir

AbbVie

Preclinical

1 5

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 6

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 7

Nuvigil

NNuvo Research GmbH

Preclinical

1 8

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

—9

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—10

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 1Not yet recruiting

Esophageal Carcinoma

NCT07726212

Q1 2029

PreclinicalRecruiting

Metastatic Soft-Tissue Sarcoma

NCT06797999

Clinical

Trials by Indication[1]

Advanced Refractory Solid Tumors1 trial

Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors

Recruiting·MMBrace Therapeutics·Phase 1/2·NCT06014658·130 enrolled

Lymphoma1 trial

Immunotherapy in Lymphoma

Recruiting·SSung-Soo Park··NCT06796517·72 enrolled

Treatment Outcome1 trial

Quality of Life and Treatment Outcomes in RRMM Patients Receiving Advanced vs. Conventional Immunotherapies

Recruiting·SSung-Soo Park··NCT07051850·174 enrolled

Sepsis1 trial

Evaluation of Reporting of Antibody-Drug Conjugate Associated Sepsis-related Toxicities

Completed·—··NCT05349383·24,618 enrolled

Metastatic Soft-tissue Sarcoma1 trial

A First-in-human, Phase 1/2, Multicenter, Open-label, Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of ADCE-D01, a Humanized Anti-human uPARAP Antibody Linked to a Topoisomerase I Inhibitor, in Patients With Metastatic and/or Unresectable Soft Tissue Sarcoma

Recruiting·AAdcendo ApS·Preclinical·NCT06797999·270 enrolled

1 more indication

Esophageal Carcinoma1 trial

A First-in-human (FIH), Open-Label, Dose Escalation and Expansion Cohorts Study to Evaluate the Safety, Tolerability, Pharmacokinetic (PK) Characteristics, and Preliminary Efficacy of MC002 in Participants With Locally Advanced/Metastatic Solid Tumors

Not yet recruiting·HHangzhou MacroLink Biopharmaceutical LLC·Phase 1·NCT07726212·143 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Antibody-Drug Conjugate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Antibody-Drug Conjugate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Antibody-Drug Conjugate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — MBrace Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: MMBrace Therapeutics

Antibody-Drug Conjugate

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Q1 2029

Trials by Indication[1]

Advanced Refractory Solid Tumors1 trial

Lymphoma1 trial

Treatment Outcome1 trial

Sepsis1 trial

Metastatic Soft-tissue Sarcoma1 trial

Esophageal Carcinoma1 trial

References

Drug Info

Quick Facts

Related News